Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.

@article{Yapa2014PulmonaryAS,
  title={Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.},
  author={S. T. W. S. Yapa and Jichang Li and Kashyap Patel and John Wilson and Michael Joseph Dooley and Johnson George and Denise C Clark and Susan Elizabeth Poole and Elyssa Williams and Christopher J. H. Porter and Roger L. Nation and Michelle P Mcintosh},
  journal={Antimicrobial agents and chemotherapy},
  year={2014},
  volume={58 5},
  pages={2570-9}
}
The purpose of this study was to define the pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following intravenous (i.v.) and inhaled administration in cystic fibrosis (CF) patients. Six CF subjects were administered nebulized CMS doses of 2 and 4 million IU and an i.v. CMS infusion of 150 mg of colistin base activity. Blood plasma, sputum, and urine samples were collected for 12 to 24 h postdose. To assess the tolerability of the drug, lung… CONTINUE READING